Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. (Q45929870)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

title

Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

Xavier Montalban

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

author name string

G Comi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

P O'Connor

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

A de Vera

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

B Eckert

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

L Kappos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

publication date

4 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

6 February 2020

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

1341-1350

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

The use of quality of life measures in multiple sclerosis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Quality of life as a predictor for change in disability in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

The Goldman Consensus statement on depression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Depression in multiple sclerosis: a quantitative review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Depression in multiple sclerosis: review and theoretical proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Quality of life and impairment in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Responsiveness of patient-based and external rating scales in multiple sclerosis: head-to-head comparison in three clinical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Factor structure, concurrent validity, and internal consistency of the Beck Depression Inventory-Second Edition in a sample of college students

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Fatigue in multiple sclerosis: definition, pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Is there a differential impact of fatigue and physical disability on quality of life in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Prevalence of 'poor sleep' among patients with multiple sclerosis: an independent predictor of mental and physical status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Fatigue in multiple sclerosis is related to disability, depression and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Depression and immunity: inflammation and depressive symptoms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Depression and Cognitive Impairment in Disability-Free Early Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

Emerging oral therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1352458511411061

21 January 2018

Identifiers

DOI

10.1177/1352458511411061

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21727148 AND SRC:MED&resulttype=core&format=json

6 February 2020

1 reference